$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000094480914000008 Filed on May 09, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$23.55M	$22.27M	$31.38M
YoY Change	-1.16%	-29.01%	257.48%
Cost Of Revenue	$12.57M	$12.39M	$11.76M
YoY Change	-4.11%	5.39%	135.14%
Gross Profit	$10.98M	$9.883M	$38.15M
YoY Change	-73.74%	-74.09%	116.46%
Gross Profit Margin	46.63%	44.37%	121.59%
Selling, General & Admin	$14.87M	$13.81M	$12.42M
YoY Change	7.17%	11.17%	164.34%
% of Gross Profit	135.46%	139.76%	32.57%
Research & Development	$16.23M	$20.99M	$9.910M
YoY Change	69.87%	111.85%	106.46%
% of Gross Profit	147.85%	212.43%	25.98%
Depreciation & Amortization	$4.027M	$3.564M	$3.429M
YoY Change	16.69%	3.94%	49.09%
% of Gross Profit	36.68%	36.06%	8.99%
Operating Expenses	$58.43M	$52.55M	$38.15M
YoY Change	39.77%	37.75%	202.77%
Operating Profit	-$34.89M	-$30.28M	-$6.773M
YoY Change	93.99%	347.02%	-21.34%
Interest Expense	$6.300M	-$14.00M	-$26.40M
YoY Change	-29.21%	-46.97%	8700.0%
% of Operating Profit
Other Income/Expense, Net	$9.279M	-$12.14M	-$24.06M
YoY Change	-45.18%	-49.52%	-1950.46%
Pretax Income	-$25.61M	-$42.42M	-$30.83M
YoY Change	2322.52%	37.6%	290.24%
Income Tax	$101.0K	$614.0K	$43.00K
% Of Pretax Income
Net Earnings	-$25.48M	-$44.55M	-$34.22M
YoY Change	650.74%	30.21%	297.85%
Net Earnings / Revenue	-108.22%	-200.01%	-109.05%
Basic Earnings Per Share	-$0.06	-$0.11
Diluted Earnings Per Share	-$0.08	-$0.11	-$109.3K
COMMON SHARES
Basic Shares Outstanding	413.8M shares	412.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$134.0M	$156.4M	$181.6M
YoY Change	-20.76%	-13.88%	192.43%
Cash & Equivalents	$134.0M	$156.4M	$181.6M
Short-Term Investments
Other Short-Term Assets	$2.613M	$5.655M	$11.90M
YoY Change	-86.25%	-52.48%	340.74%
Inventory	$18.33M	$18.87M	$23.02M
Prepaid Expenses
Receivables	$23.11M	$19.66M	$21.17M
Other Receivables	$1.900M	$1.800M	$0.00
Total Short-Term Assets	$183.0M	$205.3M	$237.7M
YoY Change	-20.47%	-13.64%	139.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.35M	$16.88M	$16.75M
YoY Change	4.65%	0.78%	216.04%
Goodwill	$226.0M	$226.1M	$82.71M
YoY Change	175.32%	173.32%
Intangibles
YoY Change
Long-Term Investments	$27.40M	$28.90M	$28.50M
YoY Change	2.62%	1.4%	182.18%
Other Assets	$4.910M	$6.520M	$2.863M
YoY Change	76.36%	127.73%	120.23%
Total Long-Term Assets	$1.144B	$1.150B	$416.3M
YoY Change	178.39%	176.38%	214.87%
TOTAL ASSETS
Total Short-Term Assets	$183.0M	$205.3M	$237.7M
Total Long-Term Assets	$1.144B	$1.150B	$416.3M
Total Assets	$1.327B	$1.356B	$653.9M
YoY Change	107.01%	107.31%	182.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.04M	$14.70M	$11.29M
YoY Change	-13.78%	30.2%	130.35%
Accrued Expenses	$54.96M	$58.77M	$26.67M
YoY Change	77.05%	120.34%	156.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.40M	$11.03M	$20.26M
YoY Change	-14.19%	-45.56%	42.7%
Total Short-Term Liabilities	$79.40M	$84.50M	$58.22M
YoY Change	33.52%	45.13%	96.04%
LONG-TERM LIABILITIES
Long-Term Debt	$2.948M	$3.101M	$196.4M
YoY Change	-98.44%	-98.42%
Other Long-Term Liabilities	$218.5M	$215.1M	$79.51M
YoY Change	171.07%	170.58%	412.98%
Total Long-Term Liabilities	$334.9M	$439.9M	$275.9M
YoY Change	24.42%	59.44%	1680.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$79.40M	$84.50M	$58.22M
Total Long-Term Liabilities	$334.9M	$439.9M	$275.9M
Total Liabilities	$414.3M	$524.4M	$334.2M
YoY Change	26.07%	56.95%	540.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$573.2M	-$547.7M	-$423.0M
YoY Change	34.44%	29.49%
Common Stock	$4.271M	$4.154M	$3.388M
YoY Change	25.95%	22.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$4.051M	$7.300M	$7.457M
YoY Change	-45.68%	-2.11%
Treasury Stock Shares	1.245M shares	2.245M shares
Shareholders Equity	$917.4M	$835.2M	$320.8M
YoY Change
Total Liabilities & Shareholders Equity	$1.327B	$1.356B	$653.9M
YoY Change	107.01%	107.31%	182.36%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$25.48M	-$44.55M	-$34.22M
YoY Change	650.74%	30.21%	297.85%
Depreciation, Depletion And Amortization	$4.027M	$3.564M	$3.429M
YoY Change	16.69%	3.94%	49.09%
Cash From Operating Activities	-$21.90M	-$22.61M	-$14.75M
YoY Change	265.0%	53.35%	28.22%
INVESTING ACTIVITIES
Capital Expenditures	-$1.600M	-$900.0K	-$800.0K
YoY Change	23.08%	12.5%	300.0%
Acquisitions		$200.0K	-$78.00K
YoY Change		-356.41%
Other Investing Activities	-$1.500M	-$1.297M	-$2.528M
YoY Change	-97.11%	-48.69%	-85.72%
Cash From Investing Activities	-$3.000M	-$264.0K	-$649.0K
YoY Change	-94.36%	-59.32%	-96.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.500M	-$6.531M	$169.6M
YoY Change	-175.76%	-103.85%	3362.06%
NET CHANGE
Cash From Operating Activities	-21.90M	-$22.61M	-$14.75M
Cash From Investing Activities	-3.000M	-$264.0K	-$649.0K
Cash From Financing Activities	2.500M	-$6.531M	$169.6M
Net Change In Cash	-22.40M	-$29.41M	$154.2M
YoY Change	-64.16%	-119.06%	-729.58%
FREE CASH FLOW
Cash From Operating Activities	-$21.90M	-$22.61M	-$14.75M
Capital Expenditures	-$1.600M	-$900.0K	-$800.0K
Free Cash Flow	-$20.30M	-$21.71M	-$13.95M
YoY Change	331.91%	55.69%	23.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1985000	USD
CY2014Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	605000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13414000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	14696000	USD
CY2014Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	21230000	USD
CY2013Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	21652000	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19664000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19767000	USD
CY2013Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4399000	USD
CY2014Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5451000	USD
CY2013Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	702000	USD
CY2014Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	124000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	58772000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	65874000	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1108000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	402000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3418000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1399000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1379383000	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1384694000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1885000	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1566000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	177000	USD
CY2013Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	145000	USD
CY2013Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2714000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2744000	USD
CY2013Q4	us-gaap	Assets Assets	1391516000	USD
CY2014Q1	us-gaap	Assets Assets	1355692000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	205272000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	242728000	USD
CY2014Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	12002000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	12062000	USD
CY2014Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	4745000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	4301000	USD
CY2014Q1	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	1300000	USD
CY2013Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-41379000	USD
CY2013Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	31376000	USD
CY2013Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1344000	USD
CY2014Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2610000	USD
CY2013Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	71600000	USD
CY2014Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	71000000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	185798000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156396000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27361000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181596000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-29402000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	154235000	USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	414818195	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	415346120	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	4148000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	4154000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33898000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46570000	USD
CY2014Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2013Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	24386000	USD
CY2013Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	211912000	USD
CY2014Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	224801000	USD
CY2014Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12391000	USD
CY2013Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11757000	USD
CY2014Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.03
CY2014Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2013Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	98000	USD
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	8300000	USD
CY2014Q1	us-gaap	Deferred Revenue DeferredRevenue	8600000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7639000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8112000	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	166068000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	166435000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3564000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3429000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	4000	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-12000	USD
CY2014Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3847
CY2014Q1	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	11100000	USD
CY2014Q1	us-gaap	Equity Method Investment Summarized Financial Information Assets EquityMethodInvestmentSummarizedFinancialInformationAssets	119100000	USD
CY2014Q1	us-gaap	Equity Method Investment Summarized Financial Information Liabilities EquityMethodInvestmentSummarizedFinancialInformationLiabilities	41200000	USD
CY2014Q1	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	12500000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	24403000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	26819000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	74533000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	71921000	USD
CY2013Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	340000	USD
CY2014Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	976000	USD
CY2014Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-10515000	USD
CY2013Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-23549000	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	2347000	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1273000	USD
CY2014Q1	us-gaap	Goodwill Goodwill	226062000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	226373000	USD
CY2014Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2014Q1	us-gaap	Goodwill Other Changes GoodwillOtherChanges	-311000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-30829000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-42421000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-45091000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-34762000	USD
CY2014Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2056000	USD
CY2013Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3890000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	614000	USD
CY2013Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-118000	USD
CY2014Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	377000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1479000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-103000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	557000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	558000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-440000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8007000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1676000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1439000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1429000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-71000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2570000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1145000	USD
CY2013Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	793341000	USD
CY2014Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	793339000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	242000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	2420000	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12880000	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	13374000	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	18865000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	18079000	USD
CY2013Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4132000	USD
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5355000	USD
CY2014Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	482000	USD
CY2013Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	777000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1350000	USD
CY2014Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1112000	USD
CY2014Q1	us-gaap	Inventory Write Down InventoryWriteDown	337000	USD
CY2013Q1	us-gaap	Inventory Write Down InventoryWriteDown	939000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	524443000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	518537000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6773000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15878000	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12705000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1391516000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1355692000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	91850000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	84500000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	426687000	USD
CY2014Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	439943000	USD
CY2013Q4	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	9061000	USD
CY2014Q1	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	8147000	USD
CY2014Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	14556000	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	11032000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	12562000	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3101000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3270000	USD
CY2014Q1	us-gaap	Long Term Investments LongTermInvestments	35697000	USD
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	30653000	USD
CY2014Q1	us-gaap	Minority Interest MinorityInterest	-3971000	USD
CY2013Q4	us-gaap	Minority Interest MinorityInterest	-3431000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	169641000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-96000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-649000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-264000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14745000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29046000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-44551000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-34215000	USD
CY2014Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-540000	USD
CY2013Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-547000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44551000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34635000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12144000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24056000	USD
CY2014Q1	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0	USD
CY2013Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	6151000	USD
CY2014Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	Segment
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	38149000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	52551000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-30277000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5653000	USD
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	5655000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6520000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6861000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-1466000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	323000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1801000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2019000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	900000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	553000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	335000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	414000	USD
CY2013Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	1509000	USD
CY2014Q1	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	679000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	215142000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	214775000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2331000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1817000	USD
CY2013Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	0	USD
CY2014Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	6264000	USD
CY2014Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1777000	USD
CY2013Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1303000	USD
CY2013Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-2528000	USD
CY2014Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-1297000	USD
CY2013Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	3015000	USD
CY2014Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
CY2014Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	200000	USD
CY2013Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-78000	USD
CY2013Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2500000	USD
CY2014Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	500000	USD
CY2013Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	755000	USD
CY2014Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	861000	USD
CY2013Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	420000	USD
CY2014Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10347000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19084000	USD
CY2013Q4	us-gaap	Prepaid Insurance PrepaidInsurance	892000	USD
CY2014Q1	us-gaap	Prepaid Insurance PrepaidInsurance	902000	USD
CY2014Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2013Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	170184000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	995000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1639000	USD
CY2014Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	4250000	USD
CY2013Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	8428000	USD
CY2014Q1	us-gaap	Profit Loss ProfitLoss	-45091000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16881000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17027000	USD
CY2013Q1	us-gaap	Profit Loss ProfitLoss	-34762000	USD
CY2014Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-74000	USD
CY2013Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	381000	USD
CY2014Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	553000	USD
CY2013Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	6951000	USD
CY2014Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	5985000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9910000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20994000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-547727000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-503177000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	19828000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	15527000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	22274000	USD
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	31376000	USD
CY2014Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	1970000	USD
CY2013Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	3092000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3579000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13812000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12424000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5205000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	876410000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	835220000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	872979000	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	831249000	USD
CY2013Q4	us-gaap	Supplies Supplies	945000	USD
CY2014Q1	us-gaap	Supplies Supplies	1919000	USD
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	2244923	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2264063	shares
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	7362000	USD
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	7300000	USD
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of estimates</font><font style="font-family:inherit;font-size:10pt;">. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>
CY2014Q1	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	6800000	USD
CY2013Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	6700000	USD
CY2014Q1	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	11400000	USD
CY2013Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	10400000	USD
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	312932561	shares
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	412909809	shares
CY2014Q1	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	4710000	USD
CY2013Q4	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	3342000	USD
CY2014Q1	opk	Accumulated Income Loss From Equity Method Investments AccumulatedIncomeLossFromEquityMethodInvestments	20492000	USD
CY2014Q1	opk	Available For Sale Securities Gross Unrealized And Realized Gain Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedAndRealizedGainLossAccumulatedInInvestments	13120000	USD
CY2014Q1	opk	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	3645000	USD
CY2013Q4	opk	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	3739000	USD
CY2014Q1	opk	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	150000	USD
CY2013Q4	opk	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	0	USD
CY2014Q1	opk	Availablefor Sale Securities Accumulated Gross Realized Gain Loss Net AvailableforSaleSecuritiesAccumulatedGrossRealizedGainLossNet	3762000	USD
CY2013Q4	opk	Availablefor Sale Securities Accumulated Gross Realized Gain Loss Net AvailableforSaleSecuritiesAccumulatedGrossRealizedGainLossNet	4022000	USD
CY2013Q1	opk	Business Acquisition Pro Forma Earnings Per Share Basicand Diluted BusinessAcquisitionProFormaEarningsPerShareBasicandDiluted	-0.11
CY2013Q1	opk	Business Acquisition Pro Forma Income Lossfrom Continuing Operations Per Share Basicand Diluted BusinessAcquisitionProFormaIncomeLossfromContinuingOperationsPerShareBasicandDiluted	0.11
CY2013Q1	opk	Business Acquisition Pro Forma Net Income Loss Availableto Common Stockholders BusinessAcquisitionProFormaNetIncomeLossAvailabletoCommonStockholders	-41252000	USD
CY2014Q1	opk	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration If Discount Rates Increase One Percent BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationIfDiscountRatesIncreaseOnePercent	1700000	USD
CY2014Q1	opk	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration If Estimated Future Sales Decrease Ten Percent BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationIfEstimatedFutureSalesDecreaseTenPercent	500000	USD
CY2014Q1	opk	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	25722000	USD
CY2013Q4	opk	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	28047000	USD
CY2013Q4	opk	Business Combination Deferred Acquisition Payments Netof Discount Current BusinessCombinationDeferredAcquisitionPaymentsNetofDiscountCurrent	5465000	USD
CY2014Q1	opk	Business Combination Deferred Acquisition Payments Netof Discount Current BusinessCombinationDeferredAcquisitionPaymentsNetofDiscountCurrent	840000	USD
CY2014Q1	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1100000000	USD
CY2013Q4	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1100000000	USD
CY2013Q1	opk	Common Stock Warrants Net Exercised CommonStockWarrantsNetExercised	815000	USD
CY2014Q1	opk	Common Stock Warrants Net Exercised CommonStockWarrantsNetExercised	657000	USD
CY2014Q1	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	12	institution
CY2014Q1	opk	Deferred Revenue Received From Collaboration Agreement DeferredRevenueReceivedFromCollaborationAgreement	1400000	USD
CY2014Q1	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	-43035000	USD
CY2013Q1	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	-30872000	USD
CY2013Q1	opk	Interest Expense Nonoperating InterestExpenseNonoperating	2897000	USD
CY2014Q1	opk	Interest Expense Nonoperating InterestExpenseNonoperating	3486000	USD
CY2013Q1	opk	Interest Income Nonoperating InterestIncomeNonoperating	59000	USD
CY2014Q1	opk	Interest Income Nonoperating InterestIncomeNonoperating	40000	USD
CY2012Q3	opk	Numberof Medicare Claims Includedin Post Payment Review Audit NumberofMedicareClaimsIncludedinPostPaymentReviewAudit	183	claim
CY2013Q1	opk	Revenue From Receipt Of Equity RevenueFromReceiptOfEquity	12540000	USD
CY2014Q1	opk	Revenue From Receipt Of Equity RevenueFromReceiptOfEquity	60000	USD
CY2014Q1	opk	Revenue From Sale Of Intellectual Property RevenueFromSaleOfIntellectualProperty	0	USD
CY2013Q1	opk	Revenue From Sale Of Intellectual Property RevenueFromSaleOfIntellectualProperty	12500000	USD
CY2013Q1	opk	Revenue From Transfer Of Intellectual Property RevenueFromTransferOfIntellectualProperty	12757000	USD
CY2014Q1	opk	Revenue From Transfer Of Intellectual Property RevenueFromTransferOfIntellectualProperty	476000	USD
CY2014Q1	opk	Revenue Received From Collaboration Agreement Offsetto Researchand Development RevenueReceivedFromCollaborationAgreementOffsettoResearchandDevelopment	400000	USD
CY2014Q1	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	74739	shares
CY2014Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	602665	shares
CY2014Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	527926	shares
CY2013Q4	opk	Taxes Recoverable Current TaxesRecoverableCurrent	3458000	USD
CY2014Q1	opk	Taxes Recoverable Current TaxesRecoverableCurrent	1266000	USD
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000944809
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	413750781	shares
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	Opko Health, Inc.

Files In Submission

Name	View Source	Status
0000944809-14-000008-index-headers.html	Edgar Link	pending
0000944809-14-000008-index.html	Edgar Link	pending
0000944809-14-000008.txt	Edgar Link	pending
0000944809-14-000008-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
opk-20140331.xml	Edgar Link	completed
opk-20140331.xsd	Edgar Link	pending
opk-20140331_cal.xml	Edgar Link	unprocessable
opk-20140331_def.xml	Edgar Link	unprocessable
opk-20140331_lab.xml	Edgar Link	unprocessable
opk-20140331_pre.xml	Edgar Link	unprocessable
opk-3312014x10q.htm	Edgar Link	pending
opk-3312014xex311.htm	Edgar Link	pending
opk-3312014xex312.htm	Edgar Link	pending
opk-3312014xex321.htm	Edgar Link	pending
opk-3312014xex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2014 Q2 Form 10-Q Financial Statement

#000094480914000008 Filed on May 09, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2014 Q2 Form 10-Q Financial Statement

#000094480914000008 Filed on May 09, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk